Abeta Epitope DNA and Peptide Vaccination: Bridging the ‘Therapeutic Threshold’ for Cognitive Aging and Alzheimer’s Disease
Immunotherapeutic clearance of beta-amyloid is the preferred regenerative medicine approach to the treatment and prevention of Alzheimer’s disease (AD), but existing attempts to develop such therapies have been fraught with side-effects and limited efficacy, as well as concerns about clinical translatability. A new approach using DNA vaccines is showing great promise, and has the potential to be safe and cheap enough for deployment in pre-clinical AD – before any irreversible memory loss can occur.
